Unlocking the power of the immune system against cancer and autoimmune disease.

A Global Leader in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Latest press releases.

October 29th 2024

Immutep Quarterly Activities Report Q1 FY25
October 28th 2024

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
October 17th 2024

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
more

About us.

our science.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on immunotherapy’s promise to drive superior clinical outcomes for patients.

our pipeline.

We have three clinical-stage & two earlier stage candidates, reflecting our unique ability to harness the LAG-3 immune checkpoint in multiple ways to stimulate or suppress the immune system.

investors & media.

We are dedicated to leveraging our technology to develop innovative treatment options for patients and to maximise value to shareholders. Learn more.